| Identification | Back Directory | [Name]
Tafasitamab | [CAS]
1422527-84-1 | [Synonyms]
Tafasitamab
Research Grade Tafasitamab
Research Grade Tafasitamab(DHD10803) |
| Hazard Information | Back Directory | [Uses]
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2]. | [in vivo]
Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models[1]. | Animal Model: | Disseminated Raji model[1]. | | Dosage: | 2.5 μg/kg | | Administration: | Tafasitamab (SC, once on Day 1, 2.5 μg/kg) | | Result: | Showed antitumor activity in disseminated Raji model. |
| Animal Model: | Disseminated Ramos model[1]. | | Dosage: | 10 mg/kg | | Administration: | Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg) | | Result: | Showed antitumor activity in disseminated Ramos model. |
| [storage]
Store at -20°C | [References]
[1] Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29. DOI:10.1007/s00262-022-03165-w
[2] Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res DOI:10.1158/0008-5472.CAN-08-2268 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|